This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Response Genetics Announces Presentation Of Lung Cancer Study Results At 2012 American Society Of Clinical Oncology Annual Meeting

Stocks in this article: RGDX

Response Genetics, Inc. (NASDAQ:RGDX), a company focused on the development and sale of molecular diagnostic tests for cancer, announced today four presentations to be held during the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL from June 1 to June 5, 2012. Study results are based on the company’s proprietary technology and approach.

“Data to be presented at ASCO 2012 will highlight the clinical utility of Response Genetics’ tests in the fight against cancer,” said Stephanie H. Astrow, Ph.D., MBA, vice president for R&D. “Through rapid and accurate assessment of genetic biomarkers, we’re helping doctors personalize cancer care by providing them valuable insights into potential cancer recurrence and tumor response to drugs such as pemetrexed and crizotinib.”

All studies presented used technology developed by Response Genetics to isolate nucleic acids from formalin-fixed, paraffin-embedded (FFPE) archived tissue for quantitative RT-PCR analysis of gene expression and other genetic analyses. Following is a summary of presentations:

Poster Discussion Sections

Monday June 4, 11:30 a.m. to 12:30 p.m., E450a

Abstract No. 4563: Generation of a prognostic cancer stem-like gene expression signature in men undergoing radical prostatectomy for localized prostate cancer. Fairey, AS, Yang, D, et al.

Genes typically expressed by cancer stem-like cells were analyzed to determine their potential as predictive biomarkers of prostate cancer recurrence after radical resection. In this study , twelve candidate genes were evaluated in 241 tumor samples, with results identifying a novel three-gene expression signature (Axin2, NANOG, CTNNB1) with potential predictive benefit.

General Poster Sections

Saturday June 2, 1:15 p.m. to 5:15 p.m., S Hall A2

Abstract No: 7066: Prospective study of tumor suppressor gene (TSG) methylation as a prognostic biomarker in surgically resected non-small cell lung cancer (NSCLC). Azzoli, CG, Drilon, A, et al.

To further explore the findings that promoter methylation of the certain tumor suppressor genes was associated with early recurrence in NSCLC, a prospective study was designed to analyze the methylation status of ten gene promoters (p16, CDH13, RASSF1A, APC, MGMT, WIF-1, METH-2, GSTP1, SOCS3, DAPK) and correlate status with clinical features, pathologic stage, disease-free survival (DFS) and overall survival (OS). Results showed no significant associations between promoter methylation and DFS, or OS.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,678.70 +6.10 0.03%
S&P 500 2,057.09 +5.27 0.26%
NASDAQ 4,771.7630 +13.8840 0.29%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs